Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1977 Aug;74(8):3602-6.
doi: 10.1073/pnas.74.8.3602.

Conformational requirements for dopamine-induced vasodilation

Conformational requirements for dopamine-induced vasodilation

P H Volkman et al. Proc Natl Acad Sci U S A. 1977 Aug.

Abstract

The availability of a series of semi-rigid analogs of dopamine and epinine has made it possible to investigate the conformational requirements for action on dopamine and beta2-adrenergic vascular receptors. The analogs were screened for dopamine-agonist action by intra-arterial injections into the renal vascular bed and for beta2-adrenergic activity by similar injections into the femoral vascular bed in dogs pretreated with phenoxybenzamine. 2-Amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (A-6,7-DTN) and its N-methyl derivative (analogous to the trans beta rotamer of dopamine) exhibited pronounced dopamine-agonist activity and minimal beta2-adrenergic activity. In contrast, the semi-rigid analog of the trans alpha rotamer of dopamine (2-amino-5,6-dihydroxy-1,2,3,4-tetrahydronaphthalene; A-5,6-DTN) and its N-methyl derivative exerted pronounced beta2-adrenergic activity but were inactive as dopamine agonists.6,7-Dihydroxytetrahydroisoquinoline, a semi-rigid analog of the cis beta rotamer of dopamine, did not produce renal vasodilation. These results indicate that a conformation of dopamine similar to that found in A-6,7-DTN is required for dopamine-vascular activity, while the conformation found in A-5,6-DTN is preferred for interaction with beta2-adrenergic receptors.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Gen Pharmacol. 1977;8(1):1-5 - PubMed
    1. Nature. 1974 Jul 19;250(463):238-41 - PubMed
    1. Br J Pharmacol. 1972 Apr;44(4):672-88 - PubMed
    1. J Med Chem. 1975 Dec;18(12):1212-6 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1975;286(4):413-28 - PubMed

Publication types

LinkOut - more resources